Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07318610 · ClinicalTrials.gov registry record · Phase 3
Reducing Adverse Vascular Outcomes With Factor XI Inhibition in Adult Participants With Peripheral Artery Disease
A Phase 3 study, sponsored by Regeneron Pharmaceuticals.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 7,050
- Enrollment target
NCT07318610 is a Phase 3 study that is actively recruiting participants, run by Regeneron Pharmaceuticals. The registered enrollment target is 7,050 participants.
The verdict
NCT07318610, a Phase 3 study, is actively recruiting participants, sponsored by Regeneron Pharmaceuticals.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 7,050 participants
- Enrollment target
Study Summary
This study is researching 2 different experimental drugs called REGN7508 and REGN9933. The study is focused on people who have Peripheral Artery Disease (PAD), which means that the blood vessels in their arms and legs have become too narrow. People with PAD have a higher risk of getting blood clots after procedures like Lower Extremity Revascularization (LER), a procedure to improve blood flow in the legs and feet. The aim of this study is to see how well REGN7508 and REGN9933 prevent life-threatening blood clots in participants with PAD who have recently had LER. The effects of REGN7508 and REGN9933, individually, will also be compared to rivaroxaban and a placebo. The study is looking at several other research questions, including: * What side effects might happen from taking the study drugs and how do they compare to the side effects of rivaroxaban * How much study drug is in the blood at different times * Whether the body makes antibodies against the study drugs (which could make the drugs less effective or could lead to side effects) * If the study drugs affect the ability of the blood to clot normally
Interventions
- DRUG Placebo
- DRUG REGN7508
- DRUG REGN9933
- DRUG Rivaroxaban
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 7,050 participants |
| Start Date | 2026-07-30 |
| Est. Completion | 2029-11-16 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07318610
The ClinicalTrials.gov registry entry for NCT07318610 describes a study currently listed as recruiting, categorized as Phase 3. The registered enrollment target is 7,050 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Regeneron Pharmaceuticals, which has 280 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Placebo is the first listed.
NCT07318610 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07318610 about?
NCT07318610 is a clinical study titled "Reducing Adverse Vascular Outcomes With Factor XI Inhibition in Adult Participants With Peripheral Artery Disease". This study is researching 2 different experimental drugs called REGN7508 and REGN9933. The study is focused on people who have Peripheral Artery Disease (PAD), which means that the blood vessels in their arms and legs have become too narrow. People with PAD have a higher risk of getting blood clots ...
What is the current status of trial NCT07318610?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 7,050 participants. The study started on 2026-07-30. Estimated completion is 2029-11-16.
What interventions are being tested in trial NCT07318610?
The interventions under investigation include: Placebo (DRUG), REGN7508 (DRUG), REGN9933 (DRUG), Rivaroxaban (DRUG).
Who is sponsoring clinical trial NCT07318610?
This trial is sponsored by Regeneron Pharmaceuticals, which has 280 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.